- Home
- NAVI vs OCUL Comparison
NAVI vs OCUL Comparison
Compare NAVI & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- OCUL
- Stock Information
- Founded
- NAVI 1973
- OCUL 2006
- Country
- NAVI United States
- OCUL United States
- Employees
- NAVI N/A
- OCUL N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- OCUL Health Care
- Exchange
- NAVI Nasdaq
- OCUL Nasdaq
- Market Cap
- NAVI 1.7B
- OCUL 1.4B
- IPO Year
- NAVI N/A
- OCUL 2014
- Fundamental
- Price
- NAVI $13.33
- OCUL $8.54
- Analyst Decision
- NAVI Sell
- OCUL Strong Buy
- Analyst Count
- NAVI 8
- OCUL 8
- Target Price
- NAVI $14.50
- OCUL $16.50
- AVG Volume (30 Days)
- NAVI 920.7K
- OCUL 797.8K
- Earning Date
- NAVI 01-29-2025
- OCUL 11-14-2024
- Dividend Yield
- NAVI 4.83%
- OCUL N/A
- EPS Growth
- NAVI N/A
- OCUL N/A
- EPS
- NAVI 0.70
- OCUL N/A
- Revenue
- NAVI $1,036,000,000.00
- OCUL $61,442,000.00
- Revenue This Year
- NAVI N/A
- OCUL $11.40
- Revenue Next Year
- NAVI $7.80
- OCUL $13.58
- P/E Ratio
- NAVI $18.99
- OCUL N/A
- Revenue Growth
- NAVI N/A
- OCUL 6.45
- 52 Week Low
- NAVI $13.16
- OCUL $3.76
- 52 Week High
- NAVI $18.94
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- NAVI 32.57
- OCUL 40.68
- Support Level
- NAVI $13.87
- OCUL $8.31
- Resistance Level
- NAVI $14.37
- OCUL $8.67
- Average True Range (ATR)
- NAVI 0.43
- OCUL 0.44
- MACD
- NAVI -0.17
- OCUL -0.04
- Stochastic Oscillator
- NAVI 7.26
- OCUL 23.64
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance and business processing solutions that simplify complex programs and help millions of people achieve success. It operates business in three segments: Federal Education Loans, Consumer Lending and Business Processing.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.